More Lumos Diagnostics Holdings Ltd. news
Lumos Diagnostics Holdings Ltd.ASX: LDX

Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study

Oct 2, 2024 at 11:53 PM EDT · Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · Oct 2, 2024 at 11:53 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/lumos-and-barda-partner-to-support-febridx-clia-waiver-study

Watch Lumos Diagnostics' latest call↗Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call↗

Lumos Diagnostics Holdings Ltd. on 6ix

Earlier from Lumos Diagnostics

  • Lumos Awarded National Contract with MediGroup for FebriDxSep 25, 2024
  • Lumos Achieves First Phase 2 Milestone in Hologic AgreementSep 20, 2024
  • Lumos Appoints Thermo Fisher Scientific as US DistributorSep 15, 2024
  • Retail Entitlement Offer BookletSep 10, 2024
  • Lumos Successfully Completes Institutional Entitlement OfferSep 5, 2024

Later from Lumos Diagnostics

  • Lumos Successfully Completes Retail Entitlement OfferOct 7, 2024
  • Lumos receives CPT PLA Code for FebriDX in the USDec 4, 2024
  • Commencement of FebriDx CLIA Waiver StudyDec 19, 2024
  • Hologic Development Agreement Expanded Scope of WorksMar 2, 2025
  • Lumos Secures Key US Reimbursement Milestones for FebriDxApr 17, 2025
All Lumos Diagnostics news releases↗

Follow Lumos Diagnostics into a list and get an email when it puts out news.

Follow Lumos Diagnostics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer